Abstract
We report a phase I/II study of weekly concurrent carboplatin and radiotherapy in patients with nasopharyngeal carcinoma (M0 stage). Of 47 patients registered, 45 completed the treatment course. Twenty-six (55%) (95% CI, 41-69%) patients experienced > or =grade 3 acute toxicity (RTOG). Five (11%) (95% CI, 2-20%) patients experienced > or =grade 3 chronic toxicity. This regimen appears to have acceptable toxicity compared to the experimental arm of Phase III Intergroup Study 0099, but progression-free and overall survival are probably inferior. At present, there is no data to suggest that carboplatin can replace cisplatin for concurrent chemoradiation for NPC.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Bacteremia / etiology
-
Carboplatin / adverse effects
-
Carboplatin / therapeutic use*
-
Carcinoma / drug therapy
-
Carcinoma / radiotherapy*
-
Chemotherapy, Adjuvant
-
Cranial Nerve Diseases / etiology
-
Disease Progression
-
Disease-Free Survival
-
Drug Administration Schedule
-
Female
-
Follow-Up Studies
-
Humans
-
Male
-
Middle Aged
-
Nasopharyngeal Neoplasms / drug therapy
-
Nasopharyngeal Neoplasms / radiotherapy*
-
Nausea / etiology
-
Neutropenia / etiology
-
Prospective Studies
-
Radiotherapy Dosage
-
Statistics as Topic
-
Survival Rate
-
Treatment Outcome
-
Vomiting / etiology
Substances
-
Antineoplastic Agents
-
Carboplatin